Genomic profile of advanced breast cancer in circulating tumour DNA
Belinda Kingston(Breast Cancer Now), Nicholas C. Turner(Royal Marsden NHS Foundation Trust), Alistair Ring(Brighton and Sussex Medical School), Richard B. Lanman(Guardant (United States)), Isaac García-Murillas(Breast Cancer Now), Michael Hubank(University College London), Iain R. Macpherson(Beatson West of Scotland Cancer Centre), Rebecca Roylance(University College London Hospitals NHS Foundation Trust), Rosalind Cutts(Institute of Cancer Research), Kimberly C. Banks(Guardant (United States)), Sarah Hrebien(Breast Cancer Now), Hannah Bye(Royal Marsden NHS Foundation Trust), Lucy Kilburn(Institute of Cancer Research), Sarah Kernaghan(Institute of Cancer Research), Laura Moretti(Institute of Cancer Research), Matthew Beaney(Breast Cancer Now), Andrew Wardley(The Christie Hospital), Claire Swift(Institute of Cancer Research), Jorge S. Reis‐Filho(Memorial Sloan Kettering Cancer Center), Giselle Walsh-Crestani(Breast Cancer Now), Richard D. Baird(Cancer Research UK), Iris Faull(Guardant (United States)), Katie Wilkinson(Institute of Cancer Research), Judith M. Bliss(Institute of Cancer Research)
Cited by 95
Related Papers
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
|The Lancet|2010|1.6k
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
|New England Journal of Medicine|2015|1.6k
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
|The Lancet|2007|1.5k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k